ST. LOUIS — Geneoscopy, Inc., a life sciences company developing diagnostic tests for gastrointestinal health, announced that Exact Sciences has withdrawn its motion for a preliminary injunction that sought to block commercialization of Geneoscopy’s ColoSense colorectal cancer screening test.
The injunction motion, filed in July 2024, focused on U.S. Patent No. 11,634,781 and U.S. Patent No. 11,970,746. By withdrawing the request, Exact Sciences effectively clears the way for Geneoscopy to expand access to ColoSense without restriction.
“By taking this step, Exact Sciences confirms what we have said all along—ColoSense is grounded in innovation, not infringement,” said Andrew Barnell, co-founder and CEO of Geneoscopy. “Competition fosters scientific progress and improves patient care. We are excited to continue moving ColoSense forward, bringing a new and patient-friendly cancer screening option to market that enhances early detection and saves lives.”
The development follows other recent victories for Geneoscopy. In July, the U.S. Patent Trial and Appeal Board ruled all 20 challenged claims of the ’781 patent unpatentable. The board also decided to institute review of a second patent asserted by Exact Sciences, the ’746 patent, based on similar grounds used in the earlier ruling.
The series of rulings strengthens Geneoscopy’s position as it pushes forward with ColoSense, a stool-based, noninvasive test aimed at expanding screening options for colorectal cancer.
